Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralatrexate, Bendamustine, and TBI as RIC for Allogeneic HCT in T-Cell Lymphoma
NCT07225985Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Apr 2026
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pralatrexate in T-cell non-Hodgkin lymphoma, sponsored by Fred Hutchinson Cancer Center. Started Apr 2026; status: recruiting.
02
Drugs
pralatrexate
03
Conditions
T-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07225985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07225985.